Teal Health secured $10 million in funding to revolutionize cervical cancer screening with their innovative at-home kit. The investment brings their total funding to $23 million for the groundbreaking Teal Wand™.
Revolutionary Women’s Health Innovation Meets Critical Need
The Teal Wand represents a significant breakthrough in women’s healthcare accessibility. One in four women currently skip regular cervical cancer screenings due to various barriers.
Kara Egan, Teal Health’s CEO, emphasizes their mission: “We’re here to create a new path forward. We enable women to take control of their health with confidence and ease.”
The company’s innovation arrives at a crucial time. Recent years have seen concerning increases in cervical cancer rates as prevention and screening measures decline.
Streamlined At-Home Testing Process
The Teal Wand system simplifies cervical cancer screening through a user-friendly process. Patients can request the home collection kit upon FDA approval.
Each order includes a telehealth consultation. Healthcare professionals guide users through proper sample collection using the Teal Wand device.
After collection, users seal and ship their samples to Teal-approved laboratories. This process eliminates traditional barriers to cervical cancer screening.
Strong Backing and Recognition
Emerson Collective and Forerunner led the latest investment round. The funding supports product development and market launch preparations.
The company received significant recognition in May 2024. This included a $1.68 million SBIR grant from the National Cancer Institute.
Forerunner partner Nicole Johnson highlighted the investment’s importance: “Many healthcare experiences are not built with the end consumer as the primary customer. This feels especially true for women’s health.”
